They’d definitely be talking with multiple potential partners trying to squeeze out the best possible deal, and I believe this has been confirmed when they noted that several were waiting to make binding offers pending the FDA approval of the trial design. A common bargaining tactic can be to stretch these things out, PAR certainly has the upper hand now given how late stage it is (P3 trial approved and ready to go for a massive indication) and the fact that the share price is rapidly moving towards the point where they could technically “do it alone” via a capital raise if they deemed that the best option (probably not the best option, but at least it means that partners can’t rely on the company being desperate for a deal). At some point though they’ll have to accept the best deal they can get, as the cash will only last them into the second half of this year. Probably sign something within the next few months, but really it could be any day now.
PAR Price at posting:
59.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)